Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Thomas C. Caffrey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6707-8468; OpenAlex author ID A5012254993. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 20

  1. A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2026.218411↗
  2. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  3. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  4. Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. Co-author DOI 10.3390/cancers17060957↗
  5. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. Co-author DOI 10.1158/1535-7163.mct-23-0868↗
  6. Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202207010↗
  7. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Co-author DOI 10.1038/s41598-022-05660-7↗
  8. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Co-author DOI 10.1016/j.canlet.2021.01.015↗
  9. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  10. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  11. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. First author DOI 10.1158/1535-7163.mct-21-0368↗
  12. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Co-author DOI 10.1158/1078-0432.ccr-19-1496↗
  13. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-20-0033↗
  14. The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer. Co-author DOI 10.1002/1873-3468.13532↗
  15. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14572↗
  16. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. Co-author DOI 10.1124/jpet.118.255372↗
  17. Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Co-author DOI 10.3390/cancers12010003↗
  18. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.18632/oncotarget.8994↗
  19. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Co-author DOI 10.1073/pnas.1203339109↗
  20. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Co-author DOI 10.1158/1078-0432.ccr-10-2288↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Anthony Hollingsworth · 19 shared papers, 2011–2026 · strength 2.41
  2. Paul M. Grandgenett · 12 shared papers, 2011–2026 · strength 1.56
  3. Prakash Radhakrishnan · 10 shared papers, 2012–2025 · strength 1.21
  4. Satish Sagar · 7 shared papers, 2019–2025 · strength 0.97
  5. Divya Thomas · 5 shared papers, 2019–2021 · strength 0.55
  6. Pankaj Kumar Singh · 5 shared papers, 2011–2026 · strength 0.53
  7. Christabelle Rajesh · 2 shared papers, 2024–2025 · strength 0.42
  8. Benson Chellakkan Selvanesan · 2 shared papers, 2025–2026 · strength 0.40
  9. Jimin Min · 2 shared papers, 2025–2026 · strength 0.40
  10. Vincent Bernard · 2 shared papers, 2025–2026 · strength 0.40
  11. Anirban Maitra · 2 shared papers, 2025–2026 · strength 0.40
  12. Kyle L. McAndrews · 2 shared papers, 2021–2026 · strength 0.38
  13. Aaron M. Mohs · 2 shared papers, 2020–2025 · strength 0.36
  14. Jean L. Grem · 3 shared papers, 2020–2025 · strength 0.36
  15. Seok‐Yeong Yu · 2 shared papers, 2022–2023 · strength 0.32
  16. Clara S. Mundry · 1 shared paper, 2026 · strength 0.25
  17. Ying Huang · 1 shared paper, 2026 · strength 0.25
  18. Jayasindu Mathiyazhagan · 1 shared paper, 2025 · strength 0.25
  19. Surendra Kumar Shukla · 2 shared papers, 2021–2022 · strength 0.23
  20. Seong-Woo Bae · 1 shared paper, 2026 · strength 0.22
  21. Huamin Wang · 1 shared paper, 2026 · strength 0.22
  22. Kamiya Mehla · 3 shared papers, 2012–2021 · strength 0.21
  23. Subodh M. Lele · 2 shared papers, 2019–2021 · strength 0.19
  24. Siyuan Tang · 1 shared paper, 2023 · strength 0.18
  25. So‐Youn Kim · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.